Monitor for regulatory approval of bepirovirsen in China and any future disclosure of financial terms (upfront/milestones). The collaboration removes China commercial execution risk but provides no near-term revenue visibility. Watch for potential pipeline collaboration opportunities with SBP Group outside China.
Price Chart
Executive Summary
GSK announced an exclusive strategic collaboration with Sino Biopharmaceutical (SBP Group) via its subsidiary CTTQ to commercialize bepirovirsen, a potential first-in-class chronic hepatitis B treatment, in mainland China. The deal leverages CTTQ's commercial infrastructure covering over 5,000 medical centers and aligns with China's national hepatitis B action plan, but no upfront or milestone payments were disclosed, and the asset remains under regulatory review.
Key Facts
- Exclusive collaboration with CTTQ (SBP Group subsidiary) for bepirovirsen in mainland China
- Bepirovirsen is a potential first-in-class antisense oligonucleotide for chronic hepatitis B, under priority regulatory review in China
- CTTQ will handle importation, distribution, hospital access, and promotional activities for an initial 5.5-year term
- GSK remains marketing authorization holder and will book sales of bepirovirsen supplied to CTTQ
- GSK gains ability to review certain early-stage SBP Group pipeline assets for potential collaboration outside China
- No upfront, milestone, or royalty payments disclosed in the filing
- Chronic hepatitis B affects ~75 million people in China and is a national health priority
Financial Impact
No financial terms disclosed — deal value, upfront payments, milestones, and royalties are not specified
Risk Factors
- Regulatory approval for bepirovirsen in China is not yet granted and could be delayed or denied
- No financial terms disclosed — deal value and revenue contribution are unknown
- Competition from existing hepatitis B therapies and other pipeline candidates
- Dependence on CTTQ's commercial execution and supply chain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-004645 |
| Document: 0001654954-26-004645-index-headers.html | 0001654954-26-004645 |
| Document: 0001654954-26-004645-index.html | 0001654954-26-004645 |
| Document: 0001654954-26-004645.txt | 0001654954-26-004645 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 10, 2026 19w ago | 6-K | $25.12 $25.25 | ▲ +0.52% | ▼ −1.62% | $26.12 (+3.98%) |
Jun 9, 2026 20w ago | 6-K | $24.66 $25.50 | ▲ +3.41% | ▲ +1.60% | $26.12 (+5.92%) |
Jun 9, 2026 20w ago | 6-K | $24.66 $25.50 | ▲ +3.41% | ▲ +1.60% | $26.12 (+5.92%) |
Jun 1, 2026 21w ago | 6-K | $24.25 $24.66 | ▲ +1.69% | ▲ +4.44% | $26.12 (+7.71%) |
Jun 1, 2026 21w ago | 6-K | $24.25 $24.66 | ▲ +1.69% | ▲ +4.44% | $26.12 (+7.71%) |
May 28, 2026 21w ago | 6-K | $24.58 $24.66 | ▲ +0.33% | ▲ +0.01% | $26.12 (+6.27%) |
May 27, 2026 21w ago | 6-K | $25.57 $23.94 | ▼ −6.37% | ▼ −7.58% | $26.12 (+2.15%) |
May 26, 2026 22w ago | 6-K | $25.50 $24.25 | ▼ −4.90% | ▼ −5.99% | $26.12 (+2.43%) |
May 26, 2026 22w ago | 6-K | $25.50 $24.25 | ▼ −4.90% | ▼ −5.99% | $26.12 (+2.43%) |
May 22, 2026 22w ago | 6-K | $26.00 $24.25 | ▼ −6.73% | ▼ −8.39% | $26.12 (+0.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers